KOPRANNSEKopran Limited· PharmaceuticalsHighPositive
Announced Thu, 15 May · 15:40 IST

Kopran Limited has informed the Exchange that Board of Directors at its meeting held on May 15, 2025, recommended Final Dividend of Rs. 3.00 per equity share.

Corporate Actions View source PDF

KOPRAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Kopran Limited's Board, at its meeting on May 15, 2025, approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, along with a recommended Final Dividend of Rs. 3.00 per equity share (30% on face value of Rs. 10), subject to shareholder approval at the 66th AGM. On a consolidated basis, FY25 revenue from operations rose modestly to Rs. 629.60 crore (vs Rs. 614.59 crore in FY24), but profit after tax fell about 24% to Rs. 38.55 crore (vs Rs. 50.96 crore), with EPS at Rs. 7.99 vs Rs. 10.57 earlier. Standalone performance was weaker, with revenue dropping to Rs. 271.01 crore (from Rs. 337.46 crore) and profit falling to Rs. 26.86 crore (from Rs. 34.64 crore). The company also noted a pending scheme of amalgamation of Kopran Laboratories Limited into Kopran Limited, and issued 36,200 equity shares under ESOPs during Q4.

Likely market impact

The Rs. 3 dividend matches last year's payout, signaling a stable but not growing distribution to shareholders. However, the sharp drop in profitability on both consolidated and standalone bases is a concern and may temper positive sentiment around the dividend declaration.